Updates are available Correction dated 2018-08-06
Click to view Correction: https://doi.org/10.1007/s40267-018-0542-y
Updates are available Correction dated 2018-11-23
Click to view Correction: https://doi.org/10.1007/s40267-018-0586-z
-
Authors
Lyseng-Williamson, Katherine A. http://orcid.org/0000-0002-5104-1158
Behr, Jürgen
- License Information
-
More Information
Article History
First Online: 18 June 2018
Change Date: 23 November 2018
Change Type: Correction
Change Date: 6 August 2018
Change Type: Correction
Change Type: Correction
Change Details: A secondary analysis of survival outcomes in the modified intent-to-treat population of AMBITION.
Change Details: Correction to: Drugs & Therapy Perspectives ExternalRef removed
Change Date: 23 November 2018
Change Details: A secondary analysis of survival outcomes in the modified intent-to-treat population of AMBITION.
Compliance with ethical standards
:
: The preparation of this review was not supported by any external funding.
: K. A. Lyseng-Williamson is a salaried employee of Adis/Springer and declares no conflict of interest. J. Behr declares having received payments for consulting and lecturing from Actelion, Bayer, Biogen, Boehringer-Ingelheim, Galapagos NV, Novartis and Roche, and having received a grant from Boehringer-Ingelheim.
